| Therapeutic Hepatitis C Virus Vaccine (NCT04318379) | GeneCure Biotechnologies | 2021-04-20 |
| Triple Combination DAAs for Treating HCV GT1b Subjects (NCT02932293) | Humanity and Health Research Centre | 2016-12-01 |
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects (NCT02486406) | AbbVie | 2015-10-28 |
| Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) (NCT02578693) | Humanity and Health Research Centre | 2015-05-15 |
| Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (NCT02583685) | Humanity and Health Research Centre | 2015-05-15 |
| Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients (NCT02576314) | Humanity and Health Research Centre | 2015-05-01 |
| A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection (NCT02356562) | AbbVie | 2015-02-03 |
| DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (NCT02555943) | Humanity and Health Research Centre | 2015-02-01 |
| Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects (NCT02470858) | Humanity and Health Research Centre | 2015-01-01 |
| Neutrino Regimen for Treatment-experienced HCV GT1 Patients (NCT02480686) | Humanity and Health Research Centre | 2015-01-01 |
| SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients (NCT02473211) | Humanity and Health Research Centre | 2015-01-01 |
| Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients (NCT02482077) | Humanity and Health Research Centre | 2015-01-01 |
| Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (NCT02333292) | Valme University Hospital | 2014-12-01 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (NCT02219503) | AbbVie | 2014-09-01 |
| The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis (NCT01711164) | University Health Network, Toronto | 2014-01-01 |
| Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (NCT02023099) | AbbVie | 2013-12-01 |
| Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (NCT01866930) | Bristol-Myers Squibb | 2013-07-11 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (NCT01854528) | AbbVie | 2013-06-01 |
| Clinical Investigation of Erlotinib as an HCV Entry Inhibitor (NCT01835938) | University Hospital, Strasbourg, France | 2013-05-01 |
| An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine (NCT01911845) | AbbVie | 2013-04-01 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (NCT01854697) | AbbVie | 2013-03-01 |
| A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (NCT01833533) | AbbVie | 2013-03-01 |
| A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients (NCT01782495) | AbbVie | 2013-02-25 |
| To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) (NCT01813552) | Merck Sharp & Dohme LLC | 2013-02-01 |
| Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (NCT01813513) | Merck Sharp & Dohme LLC | 2013-01-01 |
| A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (NCT01767116) | AbbVie (prior sponsor, Abbott) | 2012-12-01 |
| A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults (NCT01715415) | AbbVie (prior sponsor, Abbott) | 2012-11-01 |
| Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients (NCT02065999) | Kirby Institute | 2012-11-01 |
| A Study to Evaluate Chronic Hepatitis C Infection (NCT01716585) | AbbVie (prior sponsor, Abbott) | 2012-11-01 |
| A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (NCT01704755) | AbbVie (prior sponsor, Abbott) | 2012-10-01 |
| Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants (NCT01700179) | Alexion Pharmaceuticals, Inc. | 2012-09-01 |
| Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382 (NCT01651767) | Janssen R&D Ireland | 2012-08-01 |
| A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (NCT01674725) | AbbVie (prior sponsor, Abbott) | 2012-08-01 |
| A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection (NCT01672983) | AbbVie (prior sponsor, Abbott) | 2012-07-01 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients (NCT01586325) | Janssen R&D Ireland | 2012-05-25 |
| Herpes Simplex Type 1 Suppression in Hepatitis C (NCT01580995) | VA Office of Research and Development | 2012-04-01 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects (NCT01563536) | AbbVie (prior sponsor, Abbott) | 2012-02-01 |
| Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) (NCT01453075) | VA Office of Research and Development | 2011-11-01 |
| A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C (NCT01194037) | HanAll BioPharma Co., Ltd. | 2011-06-23 |
| Metformin Therapy in HCV Infection (NCT02972723) | Nottingham University Hospitals NHS Trust | 2011-03-01 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (NCT01306617) | AbbVie (prior sponsor, Abbott) | 2011-02-01 |
| Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 (NCT01260350) | Gilead Sciences | 2010-12-01 |
| A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) (NCT01221298) | AbbVie (prior sponsor, Abbott) | 2010-10-01 |
| A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (NCT01225380) | Gilead Sciences | 2010-10-01 |
| Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (NCT00854087) | Tarek Hassanein | 2010-08-01 |
| Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients (NCT01055821) | Transgene | 2010-05-01 |
| A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (NCT01074008) | AbbVie (prior sponsor, Abbott) | 2010-03-01 |
| Pharmacokinetics of Vaniprevir (MK-7009) and Hepatitis C Virus RNA Levels After Vaniprevir Treatment (MK-7009-029) (NCT00954993) | Merck Sharp & Dohme LLC | 2010-01-13 |
| Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) (NCT01011166) | Merck Sharp & Dohme LLC | 2009-11-01 |
| Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy (NCT00682591) | University of Wuerzburg | 2008-07-01 |
| Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults (NCT00557583) | Virobay Inc. | 2007-11-01 |
| The Role of Dendritic Cells in Hepatitis C Infection (NCT00723242) | University College, London | 2002-04-01 |